中国P站

Microbial metabolites;Epithelial tight junctions;Mucosal inflammation;Intestinal permeability;Short-chain Fatty Acids (SCFAs);Dysbiosis;Inflammatory Bowel Disease (IBD);Metabolomics;Gut Microbiota;Butyrate

Introduction

Microbial metabolites significantly influence the integrity of epithelial tight junctions, which in turn affects chronic mucosal inflammation [1].

Specific metabolites can either strengthen or disrupt these tight junctions, modulating both intestinal permeability and inflammatory responses. The gut microbiota produces a wide variety of metabolites that can impact the expression of tight junction proteins, such as occludin and claudins, directly affecting the barrier function of the intestinal epithelium [2].

Dysbiosis, an imbalance in the gut microbiota, leads to altered metabolite production, potentially increasing intestinal permeability and contributing to the development or worsening of chronic mucosal inflammation [3].

Short-chain Fatty Acids (SCFAs), like butyrate, are vital microbial metabolites that promote tight junction integrity by enhancing tight junction protein expression and reducing inflammation [4].

However, specific microbial metabolites, including certain bile acids, can also disrupt epithelial tight junctions, increasing intestinal permeability and triggering inflammatory pathways, thus contributing to chronic mucosal inflammation [5].

Consequently, targeting microbial metabolite production offers a potential therapeutic strategy for managing chronic mucosal inflammation, achievable through dietary interventions, prebiotics, or probiotics [6].

The interplay between microbial metabolites and epithelial tight junctions is critical for maintaining gut homeostasis, and disruptions in this balance can lead to various inflammatory conditions [7].

Advanced research techniques, like metabolomics, are increasingly used to identify and characterize specific microbial metabolites influencing epithelial tight junction function in chronic mucosal inflammation [8].

The intricate interactions between microbial metabolites, epithelial tight junctions, and the immune system are key determinants in the pathogenesis of Inflammatory Bowel Diseases (IBD) [9].

Emerging research focuses on personalized interventions targeting specific microbial metabolites to restore epithelial barrier function and alleviate chronic mucosal inflammation in individual patients [10].

Description

The gut microbiota plays a crucial role in influencing the integrity of the intestinal barrier, primarily through the production of various metabolites [1]. These metabolites can either strengthen or disrupt epithelial tight junctions, which are essential for maintaining gut homeostasis and preventing the translocation of harmful substances into the bloodstream [2]. When the gut microbiota is balanced, beneficial metabolites like Short-chain Fatty Acids (SCFAs), particularly butyrate, are produced [3].

Butyrate enhances tight junction protein expression, reduces inflammation, and supports overall gut health [4]. However, dysbiosis, or an imbalance in the gut microbiota, can lead to the production of detrimental metabolites, such as certain bile acids [5]. These metabolites can disrupt epithelial tight junctions, increasing intestinal permeability and triggering inflammatory pathways [6]. This disruption can exacerbate chronic mucosal inflammation and contribute to the development of Inflammatory Bowel Diseases (IBD) [7].

The complex interplay between microbial metabolites, epithelial tight junctions, and the immune system is a critical determinant in the pathogenesis of IBD [8]. When tight junctions are compromised, the gut barrier becomes leaky, allowing bacteria and other antigens to penetrate the intestinal lining [9]. This triggers an immune response, leading to chronic inflammation and further damage to the intestinal tissue [10]. Therefore, maintaining a healthy gut microbiota and promoting the production of beneficial metabolites is crucial for preserving gut barrier function and preventing chronic mucosal inflammation [11].

Targeting microbial metabolite production represents a promising therapeutic strategy for managing chronic mucosal inflammation [12]. Dietary interventions, prebiotics, and probiotics can modulate the composition and function of the gut microbiota, promoting the production of beneficial metabolites and reducing the production of harmful ones [13]. Emerging research focuses on personalized interventions that target specific microbial metabolites to restore epithelial barrier function and alleviate chronic mucosal inflammation in individual patients [14]. Advanced research techniques, such as metabolomics, are increasingly used to identify and characterize the specific microbial metabolites that influence epithelial tight junction function in the context of chronic mucosal inflammation [15].

Conclusion

Microbial metabolites significantly impact epithelial tight junction integrity, influencing chronic mucosal inflammation. Specific metabolites can either strengthen or disrupt these tight junctions, modulating intestinal permeability and inflammatory responses. The gut microbiota produces a diverse array of metabolites that influence the expression of tight junction proteins like occludin and claudins, directly affecting the intestinal epithelium's barrier function. Dysbiosis, or an imbalance in the gut microbiota, leads to altered metabolite production, potentially increasing intestinal permeability and exacerbating chronic mucosal inflammation. Short-chain Fatty Acids (SCFAs), such as butyrate, are key microbial metabolites that promote tight junction integrity by enhancing tight junction protein expression and reducing inflammation. However, specific microbial metabolites, including certain bile acids, can disrupt epithelial tight junctions, increasing intestinal permeability and triggering inflammatory pathways, contributing to chronic mucosal inflammation. Targeting microbial metabolite production is a potential therapeutic strategy for managing chronic mucosal inflammation, achievable through dietary interventions, prebiotics, or probiotics. The interplay between microbial metabolites and epithelial tight junctions is critical for maintaining gut homeostasis, and disruptions in this balance can lead to various inflammatory conditions. Advanced research techniques like metabolomics are increasingly used to identify and characterize specific microbial metabolites influencing epithelial tight junction function in the context of chronic mucosal inflammation. The complex interactions between microbial metabolites, epithelial tight junctions, and the immune system are key determinants in the pathogenesis of Inflammatory Bowel Diseases (IBD). Emerging research focuses on personalized interventions targeting specific microbial metabolites to restore epithelial barrier function and alleviate chronic mucosal inflammation in individual patients.

References

1. Klaus RG, Rebekah A, Lena O (2019) .Inflamm Bowel Dis 25:1235-1246.

   , ,

2. Andreas W, Shilpa S, Abdullah MG (2020) .Sci Rep 10:18521.

   , ,

3. Paola P, Patrice DC (2020) .Nat Rev Microbiol 18:321-337.

   , ,

4. Heike L, Kristina G, Marie-Christin R (2021) .Nutrients 13:658.

   , ,

5. Ashish T, Saurabh D, Ying W (2018) .Inflamm Bowel Dis 24:1692-1701.

   , ,

6. Emma R, Patrizia R, Marco C (2019) .Microorganisms 7:14.

   , ,

7. Chelliah C, Jaehoon G, Seung HR (2018) .World J Gastroenterol 24:4628-4644.

   , ,

8. Tanushree S, Angel M, Saima N (2023) .World J Gastroenterol 29:2274-2291.

   , ,

9. Masato M, Atsushi N, Osamu I (2017) .Int Immunol 29:465-475.

   , ,

10. B VdH, Jerry MW (2021) .Trends Endocrinol Metab 32:48-59.

    , ,